Cargando…
The use of stem cells in ischemic heart disease treatment
Ischemic heart disease is a major cause of death and disabilities worldwide. Unfortunately, not all patients are suitable for direct revascularization. Cell-based therapies may be alternative options because of their potential to promote neovascularisation and endothelial repair, improving myocardia...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Termedia Publishing House
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6180025/ https://www.ncbi.nlm.nih.gov/pubmed/30310400 http://dx.doi.org/10.5114/kitp.2018.78446 |
_version_ | 1783362115834216448 |
---|---|
author | Litwinowicz, Radoslaw Kapelak, Bogusław Sadowski, Jerzy Kędziora, Anna Bartus, Krzysztof |
author_facet | Litwinowicz, Radoslaw Kapelak, Bogusław Sadowski, Jerzy Kędziora, Anna Bartus, Krzysztof |
author_sort | Litwinowicz, Radoslaw |
collection | PubMed |
description | Ischemic heart disease is a major cause of death and disabilities worldwide. Unfortunately, not all patients are suitable for direct revascularization. Cell-based therapies may be alternative options because of their potential to promote neovascularisation and endothelial repair, improving myocardial perfusion. The success of cell-based therapies depends on the type of implanted stem cells, delivery method and underlying disease. Several different cell populations including bone marrow-derived mononuclear cells (MNCs), mesenchymal stromal cells (MSCs), CD34+, CD133+, endothelial progenitor cells, adipose-derived mesenchymal stromal cells (ASCs) and stem cells from placenta and umbilical cord have been investigated. Presently, no consensus exists about the best cell type for clinical regenerative therapy. Because the system of coronary arteries in the ischemic area is poor and most of the coronary artery is significantly narrowed or closed, direct implantation of stem cells in the ischemic area of the heart muscle appears an attractive method. |
format | Online Article Text |
id | pubmed-6180025 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Termedia Publishing House |
record_format | MEDLINE/PubMed |
spelling | pubmed-61800252018-10-11 The use of stem cells in ischemic heart disease treatment Litwinowicz, Radoslaw Kapelak, Bogusław Sadowski, Jerzy Kędziora, Anna Bartus, Krzysztof Kardiochir Torakochirurgia Pol Review Paper Ischemic heart disease is a major cause of death and disabilities worldwide. Unfortunately, not all patients are suitable for direct revascularization. Cell-based therapies may be alternative options because of their potential to promote neovascularisation and endothelial repair, improving myocardial perfusion. The success of cell-based therapies depends on the type of implanted stem cells, delivery method and underlying disease. Several different cell populations including bone marrow-derived mononuclear cells (MNCs), mesenchymal stromal cells (MSCs), CD34+, CD133+, endothelial progenitor cells, adipose-derived mesenchymal stromal cells (ASCs) and stem cells from placenta and umbilical cord have been investigated. Presently, no consensus exists about the best cell type for clinical regenerative therapy. Because the system of coronary arteries in the ischemic area is poor and most of the coronary artery is significantly narrowed or closed, direct implantation of stem cells in the ischemic area of the heart muscle appears an attractive method. Termedia Publishing House 2018-09-24 2018-09 /pmc/articles/PMC6180025/ /pubmed/30310400 http://dx.doi.org/10.5114/kitp.2018.78446 Text en Copyright: © 2018 Polish Society of Cardiothoracic Surgeons (Polskie Towarzystwo KardioTorakochirurgów) and the editors of the Polish Journal of Cardio-Thoracic Surgery (Kardiochirurgia i Torakochirurgia Polska) http://creativecommons.org/licenses/by-nc-sa/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license. |
spellingShingle | Review Paper Litwinowicz, Radoslaw Kapelak, Bogusław Sadowski, Jerzy Kędziora, Anna Bartus, Krzysztof The use of stem cells in ischemic heart disease treatment |
title | The use of stem cells in ischemic heart disease treatment |
title_full | The use of stem cells in ischemic heart disease treatment |
title_fullStr | The use of stem cells in ischemic heart disease treatment |
title_full_unstemmed | The use of stem cells in ischemic heart disease treatment |
title_short | The use of stem cells in ischemic heart disease treatment |
title_sort | use of stem cells in ischemic heart disease treatment |
topic | Review Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6180025/ https://www.ncbi.nlm.nih.gov/pubmed/30310400 http://dx.doi.org/10.5114/kitp.2018.78446 |
work_keys_str_mv | AT litwinowiczradoslaw theuseofstemcellsinischemicheartdiseasetreatment AT kapelakbogusław theuseofstemcellsinischemicheartdiseasetreatment AT sadowskijerzy theuseofstemcellsinischemicheartdiseasetreatment AT kedzioraanna theuseofstemcellsinischemicheartdiseasetreatment AT bartuskrzysztof theuseofstemcellsinischemicheartdiseasetreatment AT litwinowiczradoslaw useofstemcellsinischemicheartdiseasetreatment AT kapelakbogusław useofstemcellsinischemicheartdiseasetreatment AT sadowskijerzy useofstemcellsinischemicheartdiseasetreatment AT kedzioraanna useofstemcellsinischemicheartdiseasetreatment AT bartuskrzysztof useofstemcellsinischemicheartdiseasetreatment |